Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Modifier Genes Modulate Inherited Cardiac Disorder
Disease Discoveries

Modifier Genes Modulate Inherited Cardiac Disorder

By Will DossMar 5, 2018
Share
Facebook Twitter Email
Alfred George, Jr., MD, chair and Magerstadt Professor of Pharmacology, director of the Center for Pharmacogenomics, was a co-author of the study that discovered how two genes modulate the severity of Long QT Syndrome, an inherited cardiac disorder.

Scientists at Northwestern and Case Western Reserve University School of Medicine have identified genes that can modify the intensity of congenital Long QT Syndrome, an inherited cardiac disorder that can cause heart arrhythmias and sudden cardiac death, according to a study published in the Journal of Clinical Investigation.

Alfred George, Jr., MD, chair and Magerstadt Professor of Pharmacology, was a co-author of the study, which according to the authors, could also serve as a paradigm for future investigations into inherited diseases.

Long QT Syndrome (LQTS) is a genetic disorder that affects the heart’s electrical cycle, elevating risk for arrhythmias and sudden cardiac death. Though it is a congenital disorder, the inheritance patterns for LQTS are complex and some people who carry disease-causing mutations remain asymptomatic, while other members of the same family experience symptoms, such as heart palpitations, fainting or cardiac arrest.

Investigating a large family from Cleveland with LQTS Type 2 caused by a known mutation in the gene KCNH2, the scientists sought possible genetic modifiers by looking for genetic variants in severely affected individuals that their mildly affected first-degree relatives lacked.

Using whole-exome sequencing coupled with patient-derived induced pluripotent stem cells (iPSC), the investigators eventually traced the symptomatic variability to differences in two genes: KCNK17 and REM2. Alone, a KCNK17 variant was observed to protect against LQTS, whereas the REM2 variant worsened the susceptibility to arrhythmia in the Cleveland family.

To confirm their findings, the scientists used gene editing to correct the REM2 variant in iPSCs and found that cardiac cell function became normal.

While LQTS is traditionally thought to be caused by a single gene, the compound effects of multiple gene variants — sometimes called a “double hit” — are well documented in LQTS and other cardiac diseases, and provide evidence that more genetic conditions might also have multiple drivers of disease. The authors note that their method — using iPSCs, next-generation exome sequencing and gene editing — might be useful to screen for genetic modifiers in populations at risk for other congenital diseases.

“The identification of modifier genes in human genetic disorders is very challenging,” said George, also director of the Center for Pharmacogenomics. “This study demonstrates successful integration of several state-of-the-art technologies that together enabled us to identify novel genetic modifiers of LQTS. We hope these results can be translated into strategies to better predict who is at highest risk for sudden death.”

This study was supported by NIH/NHLBI grant 1R01HL124245, American Heart Association Established Investigator Award 12EIA9300060, an American Heart Association Pre-Doctoral Fellowship from the Great Rivers Affiliate 15PRE25700037 and T32 Training Grant HL105338-01.

Cardiology Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023
Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Comments are closed.

Latest News

NUDOCS Program Inspires the Next Generation of Physicians

Mar 31, 2023

Women in Medicine Conference Celebrates Community

Mar 31, 2023

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.